BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2153 related articles for article (PubMed ID: 18187094)

  • 21. Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler.
    Leung E; Shenton BK; Green K; Jackson G; Gould FK; Yap C; Talbot D
    Transpl Infect Dis; 2004 Dec; 6(4):156-64. PubMed ID: 15762933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
    Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?
    Greenfield HM; Gharib MI; Turner AJ; Guiver M; Carr T; Will AM; Wynn RF
    Pediatr Blood Cancer; 2006 Aug; 47(2):200-5. PubMed ID: 16206207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation.
    Cesaro S; Murrone A; Mengoli C; Pillon M; Biasolo MA; Calore E; Tridello G; Varotto S; Alaggio R; Zanesco L; Palù G; Messina C
    Br J Haematol; 2005 Jan; 128(2):224-33. PubMed ID: 15638858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease.
    Carpentier L; Tapiero B; Alvarez F; Viau C; Alfieri C
    J Infect Dis; 2003 Dec; 188(12):1853-64. PubMed ID: 14673764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
    Guthery SL; Heubi JE; Bucuvalas JC; Gross TG; Ryckman FC; Alonso MH; Balistreri WF; Hornung RW
    Transplantation; 2003 Apr; 75(7):987-93. PubMed ID: 12698085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early evidence of lymphoproliferative disorder: post-transplant monitoring of Epstein-Barr infection in adult and pediatric patients.
    Gaeta A; Nazzari C; Verzaro S; Latte MC; Fabri G; Scateni S; Raggi C; Lubrano R; Mancini C
    New Microbiol; 2006 Oct; 29(4):231-41. PubMed ID: 17201089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
    Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
    Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical significance of peripheral blood Epstein-Barr viral load monitoring using polymerase chain reaction in renal transplant recipients.
    Toyoda M; Moudgil A; Warady BA; Puliyanda DP; Jordan SC
    Pediatr Transplant; 2008 Nov; 12(7):778-84. PubMed ID: 18331541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreasing the Epstein-Barr virus load by adjusting the FK506 blood level.
    Orii T; Ohkohchi N; Satomi S; Hoshino Y; Kimura H
    Transpl Int; 2002 Nov; 15(11):529-34. PubMed ID: 12461655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-transplant lymphoproliferative disorder following pediatric heart transplantation.
    Mendoza F; Kunitake H; Laks H; Odim J
    Pediatr Transplant; 2006 Feb; 10(1):60-6. PubMed ID: 16499589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of semiquantitative polymerase chain reaction for Epstein-Barr virus to measure virus load in pediatric organ transplant recipients with and without posttransplant lymphoproliferative disease.
    Allen U; Hebert D; Petric M; Tellier R; Tran D; Superina R; Stephens D; West L; Wasfy S; Nelson S
    Clin Infect Dis; 2001 Jul; 33(2):145-50. PubMed ID: 11418872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantification of Epstein-Barr virus-DNA load in lung transplant recipients: a comparison of plasma versus whole blood.
    Bakker NA; Verschuuren EA; Veeger NJ; van der Bij W; van Imhoff GW; Kallenberg CG; Hepkema BG
    J Heart Lung Transplant; 2008 Jan; 27(1):7-10. PubMed ID: 18187080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Asymptomatic high Epstein-Barr viral load carriage in pediatric renal transplant recipients.
    Tanaka E; Sato T; Ishihara M; Tsutsumi Y; Hisano M; Chikamoto H; Akioka Y; Dohno S; Maeda A; Hattori M; Wakiguchi H; Fujieda M
    Pediatr Transplant; 2011 May; 15(3):306-13. PubMed ID: 21492352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low viral load post-transplant lymphoproliferative disease localized within the tongue.
    Henry DD; Hunger SP; Braylan RC; Dharnidharka VR
    Transpl Infect Dis; 2008 Dec; 10(6):426-30. PubMed ID: 18657087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative Epstein-Barr virus viral load monitoring in pediatric liver transplantation.
    Jang JY; Kim KM; Lee YJ; Lee SG; Chi HS
    Transplant Proc; 2008 Oct; 40(8):2546-8. PubMed ID: 18929796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
    Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation.
    Barkholt L; Linde A; Falk KI
    Transpl Int; 2005 Jul; 18(7):835-43. PubMed ID: 15948864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
    Franco A; Jiménez L; Aranda I; Alvarez L; González M; Rocamora N; Olivares J
    Nefrologia; 2002; 22(5):463-9. PubMed ID: 12497748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 108.